<DOC>
	<DOC>NCT01147276</DOC>
	<brief_summary>The study examines whether DPP-4 inhibition by vildagliptin affects the glucagon counterregulatory response to hypoglycemia in type 1 diabetes.</brief_summary>
	<brief_title>Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes</brief_title>
	<detailed_description>Vildagliptin (50 mg BID) or placebo is given as add-on to insulin treatment for four weeks in patients with type 1 diabetes. Then, a hypoglycemic clamp (2.5 mmol/l glucose) is undertaken with the determination of glucagon.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Type 1 diabetes Age &gt;18 years HbA1c 6.58,5% Pregnancy Lactation Acute infection Liver disease Treatment with cortisol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>DPP-4</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Catecholamines</keyword>
	<keyword>Counterregulation</keyword>
	<keyword>Type 1 diabetes</keyword>
</DOC>